Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Glenmark Pharmaceuticals is currently trading at Rs. 761.00, up by 5.40 points or 0.71% from its previous closing of Rs. 755.60 on the BSE.
The scrip opened at Rs. 752.05 and has touched a high and low of Rs. 768.20 and Rs. 752.05 respectively. So far 3273 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 879.15 on 21-Sep-2023 and a 52 week low of Rs. 369.50 on 30-Jan-2023.
Last one week high and low of the scrip stood at Rs. 768.20 and Rs. 741.75 respectively. The current market cap of the company is Rs. 21320.63 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 35.15% and 18.21% respectively.
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg, the generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, of Apothecon Inc. Glenmark’s Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIATM sales data for the 12?month period ending September 2023, the Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg market achieved annual sales of approximately $18.1 million.
Glenmark’s current portfolio consists of 189 products authorized for distribution in the U.S. marketplace and 50 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.00 |
| Dr. Reddys Lab | 5780.70 |
| Cipla | 1442.00 |
| Zydus Lifesciences | 1088.45 |
| Lupin | 1683.50 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
